International Society of Liquid Biopsy (ISLB) shared a post on X about a recent paper by James Black et al. published in Nature Medicine:
Authors: James Black, Gabor Bartha, Charles Abbott, Richard Chen, Charles Swanton et al.
“Liquid Biopsy Breakthrough.
New ultrasensitive ctDNA detection tools like NeXT Personal achieve unparalleled sensitivity (1–3 ppm). This can revolutionize early-stage NSCLC management by:
- Pre-op disease stratification
- Predicting worse clinical outcomes
- Identifying ultra-low-risk patients
Study Highlights:
- 81% detection in LUAD pre-op cases.
- Significant OS impact: ctDNA presence = poorer survival.”
More posts International Society of Liquid Biopsy.
